Author:
Maeda Kojiro,Kaneko Masayuki,Narukawa Mamoru,Arato Teruyo
Funder
Health Labour Sciences Research Grant from Japan's Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference30 articles.
1. Dolgin E. Big pharma moves from ‘blockbusters’ to ‘niche busters’. Nat Med. 2010;16(8):837.
2. Torres C. Rare opportunities appear on the horizon to treat rare diseases. Nat Med. 2010;16(3):241.
3. FDA. Federal regulations 21CFR part 316. (1983). http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=0e737d105ef9a1632b19a1e713b93cc4&mc=true&n=pt21.5.316&r=PART&ty=HTML .
4. Regulation (EC) no 141/2000 on orphan medicinal products. 1999. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF . Accessed 20 Dec 2016.
5. Braun MM. Emergence of orphan drug in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010;9(7):519–22.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献